Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep (NASDAQ: IMMP) announced that the United States Patent and Trademark Office has granted a new patent (No. 12,673,088) titled “Combined Preparations for the Treatment of Cancer or Infection.” This is the fourth U.S. patent in Immutep’s series covering eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors.
The patent protects methods for treating cancer using efti with anti-PD-1 or anti-PD-L1 antibodies, or their fragments, and expires on 20 January 2036. According to Immutep, the grant strengthens its intellectual property estate for efti combinations and supports future development and business development opportunities.
Immutep (NASDAQ: IMMP) reported mature overall survival data from the INSIGHT-003 Phase I trial of eftilagimod alfa (efti) plus KEYTRUDA and chemotherapy in 1st line non-squamous NSCLC (N=51). Median overall survival (mOS) reached 30.9 months in both the overall population and patients with PD-L1 TPS <50% (N=47), and 37.8 months in TPS ≥50% (N=4). Approximately 92% of patients had TPS <50%, a group with significant unmet need, and outcomes continue to compare favourably with a 22.0‑month mOS historical benchmark for anti‑PD‑1 plus doublet chemotherapy. No new safety signal was seen.
Immutep also updated on the discontinued TACTI‑004 Phase III 1L NSCLC trial, where interim futility analysis showed an ORR of 42.9% for the efti arm versus 55.1% for control (N=173). Preliminary immune monitoring indicates a markedly different immune activation profile versus prior efti studies and INSIGHT‑003. Root cause analysis, including manufacturing factors, is ongoing, with further results expected in Q3 CY2026.
Immutep (NASDAQ: IMMP) reported positive interim Phase I data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. In healthy volunteers, the randomized, placebo-controlled study met its primary safety endpoint and showed favourable tolerability across single ascending doses.
IMP761 demonstrated statistically significant pharmacodynamic activity at 7 mg/kg (p = 0.029) in a validated KLH immune challenge model, reduced local inflammation, and attenuated T-cell activity. Pharmacokinetics support once-every-4-weeks dosing, backing progression toward Phase II. Data are being presented at EULAR 2026 in London.
Immutep (NASDAQ: IMMP) reported pooled results from five clinical trials of eftilagimod alfa (efti) plus standard-of-care in 5,922 late-stage cancer patients. Efti 30 mg SC increased absolute lymphocyte count (ALC) versus SOC alone, and ALC responders in the efti+SOC group showed a median overall survival improvement of +7.7 months (p=0.00171) over non-responders.
Efti treatment was also linked to higher TH1 biomarkers and enhanced T-cell function, suggesting broad immune activation associated with improved clinical benefit across multiple tumor types. Separately, Immutep discontinued the TACTI-004 Phase III trial in March 2026 after an interim futility analysis.
Immutep (NASDAQ: IMMP / ASX: IMM) announced discontinuation of the TACTI-004 Phase III 1L NSCLC trial after an IDMC-recommended interim futility analysis, with a root cause review underway through Q3 CY2026. Cash and term deposits total A$110.6 million, providing runway into H1 CY2028; IMP761 Phase I shows favourable safety and moves to MAD, with data due at EULAR June 2026. The Company expects a US$10 million payment obligation to Dr. Reddy’s in June 2026 and is implementing cost reductions while winding down TACTI-004.
Immutep (NASDAQ: IMMP) received a Nasdaq notice that its American Depositary Shares failed to meet the US$1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days ended April 24, 2026.
Nasdaq has given an initial 180-calendar-day compliance period through October 26, 2026, during which Immutep must achieve a closing ADS bid of at least US$1.00 for ten consecutive business days to regain compliance. Trading and the company’s ASX listing remain unaffected. The company will monitor the ADS price and consider options but stated there is no assurance it will regain compliance.
Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026. The poster, titled “Impact of eftilagimod alfa…on lymphocyte activation and survival outcomes in metastatic cancer patients,” is scheduled for 30 May 2026, 1:30 PM–4:30 PM CDT, Poster Board 359, Abstract #2569.
The presentation will report cumulative clinical and translational data across multiple late-stage cancer studies indicating that eftilagimod alfa (efti), an APC activator via MHC class II, induces rapid and sustained lymphocyte activation associated with improved overall survival in metastatic patients.
Immutep (NASDAQ: IMMP) announced the FDA has granted Orphan Drug Designation for eftilagimod alfa (efti) to treat soft tissue sarcoma (STS) on April 15, 2026. The designation may provide regulatory support, tax credits, fee waivers and seven years of market exclusivity if approved.
Immutep cited investigator‑initiated Phase II EFTISARC‑NEO data in 38 evaluable patients showing median tumour hyalinization/fibrosis of 51.5%, above the pre‑specified 35% target and historical ~15% with radiotherapy alone; the study reported immune activation signals and a favourable safety profile without surgery delays.
Immutep (NASDAQ: IMMP) reported successful completion of the single ascending dose (SAD) portion of its first‑in‑human Phase I study of IMP761, a LAG‑3 agonist for autoimmune diseases, with dosing up to 14 mg/kg and no dose‑limiting toxicities observed.
The multiple ascending dose (MAD) portion is ongoing, with MAD completion expected in Q3 2026. According to the company, IMP761 produced a durable immunosuppressive effect in an intradermal antigen challenge after a single administration. Phase I data will be presented at EULAR on 4 June 2026.
Immutep (NASDAQ: IMMP) announced on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study in first-line non-small cell lung cancer after a planned interim futility analysis.
Enrollment will be halted, the study will be wound down with patient follow-up and site close-out, and Immutep says it is reviewing the data and next steps. The company now expects its cash runway to extend well beyond its prior guidance of Q2 CY2027 and will provide an updated outlook after operational assessments.